不同时机运用瑞舒伐他汀在静脉溶栓治疗急性脑梗死的疗效及安全性分析

Therapeutic effect and safety analysis of use of rosuvastatin at different times in treatment of acute cerebral infarction in intravenous thrombolysis

目的研究不同时机运用瑞舒伐他汀在静脉溶栓治疗急性脑梗死的疗效及安全性分析。方法本研究观察对象为2017年2月—2019年2月濮阳市安阳地区医院收治的84例急性脑梗死患者,按就诊顺序随机分为观察组与对照组,观察组静脉溶栓治疗前给予瑞舒伐他汀,对照在静脉溶栓治疗后给予瑞舒伐他汀,连续治疗2个月。评价两组患者综合临床疗效,记录治疗前后神经功能缺损(NHISS)评分、日常生活活动能力(ADL)评分,治疗前后检测外周血清高迁移率族蛋白1(HMGB1)、白细胞介素6(IL-6)等炎性因子水平,记录治疗期间不良反应情况。结果观察组治疗总有效率为85.71%,显著高于对照组(73.81%),差异具有统计学意义(P<0.05);两组治疗后NHISS评分均显著降低,ADL评分显著升高,差异具有统计学意义(P<0.05);两组治疗后血清HMGB1、IL-6、MMP-9、肿瘤坏死因子(TNF-a)、高敏C反应蛋白(hs-CRP)水平均显著降低,且治疗后观察组显著低于对照组,差异具有统计学意义(P<0.05);两组不良反应发生率以及再出血率差异无统计学意义(P>0.05)。结论静脉溶栓治疗前给予瑞舒伐他汀能显著提升治疗效果,提高患者神经功能以及活动能力,降低机体炎症反应,治疗安全有效。

Objective To study the therapeutic effect and safety analysis of the use of rosuvastatin at different Times in the treatment of acute cerebral infarction in intravenous thrombolysis.Methods Eighty-four patients with acute cerebral infarction treated in our hospital from February 2017 to February 2019 were selected as our objects and randomly divided into the observation group and the control group according to the order of visits. The observation group was treated with rosuvastatin before the treatment of intravenous thrombolysis.The control group was treated with rosuvastatin after the treatment of intravenous thrombolytic. They were continuously treated for 2 months. The clinical efficacy of the two groups was evaluated. Neurological impairment(NHISS) scores and ADL scores were recorded before and after treatment. Peripheral serum high mobility group box 1(HMGB1) and interleukin-6(IL-6) were measured before and after treatment. Adverse reactions were recorded during the treatment.Results The total effective rate in the observation group was 85.71%, which was significantly higher than that in the control group(73.81%). The difference was statistically significant(P<0.05). After treatment, the NHISS scores significantly decreased, and the ADL score significantly increased. The difference was statistically significant(P<0.05);Serum HMGB1, IL-6, MMP-9, tumor necrosis factor(TNF-a) and high-sensitivity C-reactive protein(hs-CRP) levels significantly decreased after treatment in both groups, and the observation group was significantly lower than the control group, and the difference was statistically significant(P<0.05);There was no significant difference in the incidence of adverse reactions and rebleeding rate between the two groups(P>0.05).Conclusion The use of rosuvastatin before intravenous thrombolysis can significantly improve the therapeutic effect, the patient’s neurological function and activity and reduce the body’s inflammatory response, being safe and effective.